



## PHARMACEUTICAL 2021










## PHARMACEUTICAL 2021





The relative strengths and weaknesses of AYTU BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AYTU BIOPHARMA INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 151% points. The greatest weakness of AYTU BIOPHARMA INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 47%, being 401% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	74,966
Cost of Goods Sold	7,553
Intangible Assets	28,090
Liabilities, Current	28,307
Liabilities, Non-Current	5,457
Other Assets	49,522
Other Compr. Net Income	0
Other Expenses	4,686
Other Liabilities	24,057
Other Net Income	7,510
Property and Equipment	259
Research and Development	1,721
Revenues	27,632
Selling, General and Administrative Expense	34,802

Output Variable	Value in 1000 USD
Assets	152,836
Liabilities	57,821
Expenses	48,763
Stockholders Equity	95,015
Net Income	-13,621
Comprehensive Net Income	-13,621
Economic Capital Ratio	47%